According to research, metformin may selectively target cancer stem cells (CSCs) over non-stem cancer cells (NSCCs), as it inhibits inflammatory pathways such as NF-κB and IL6 in CSCs, resulting in selective CSC death and tumor growth reduction. Here, IL6 is linked to neoplasm.